Haemonetics Corporation

NYSE:HAE 株式レポート

時価総額:US$4.3b

Haemonetics バランスシートの健全性

財務の健全性 基準チェック /26

Haemoneticsの総株主資本は$878.9M 、総負債は$1.2Bで、負債比率は139.6%となります。総資産と総負債はそれぞれ$2.5Bと$1.6Bです。 Haemoneticsの EBIT は$213.2Mで、利息カバレッジ比率14.1です。現金および短期投資は$300.0Mです。

主要情報

139.6%

負債資本比率

US$1.23b

負債

インタレスト・カバレッジ・レシオ14.1x
現金US$300.03m
エクイティUS$878.85m
負債合計US$1.65b
総資産US$2.53b

財務の健全性に関する最新情報

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

財務状況分析

短期負債: HAEの 短期資産 ( $955.9M ) が 短期負債 ( $273.9M ) を超えています。

長期負債: HAEの短期資産 ( $955.9M ) は 長期負債 ( $1.4B ) をカバーしていません。


デット・ツー・エクイティの歴史と分析

負債レベル: HAEの 純負債対資本比率 ( 105.4% ) は 高い と見なされます。

負債の削減: HAEの負債対資本比率は、過去 5 年間で65.3%から139.6%に増加しました。

債務返済能力: HAEの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 6.9% )。

インタレストカバレッジ: HAEの負債に対する 利息支払いEBIT ( 14.1 x coverage) によって 十分にカバーされています


貸借対照表


健全な企業の発掘